









市場行情
/
股票
/
nasdaq-qgen
/

Qiagen NV

QGEN

48.290USD

-0.160-0.33%

收盤 01/09, 16:00（美東）報價延遲15分鐘

10.45B總市值

25.83本益比TTM



Qiagen NV

48.290

-0.160-0.33%

概覽公司財務分析

概覽

公司

財務

分析

關於 Qiagen NV 公司

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Qiagen NV簡介



公司代碼QGEN

公司名稱Qiagen NV

上市日期Sep 01, 1996

CEOBernard (Thierry)

員工數量5765

證券類型Ordinary Share

年結日Sep 01

公司地址Hulsterweg 82

城市VENLO

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家Netherlands

郵編5912 PL

電話31773556600

網址https://www.qiagen.com/

公司代碼QGEN

上市日期Sep 01, 1996

CEOBernard (Thierry)

Qiagen NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Board

383.09K

+143556.00%

Mr. Thierry Bernard

Chief Executive Officer, Managing Director, Member of the Executive Board

312.13K

+134537.00%

Dr. Metin Colpan, Ph.D.

Independent Member of the Supervisory Board

171.79K

-227680.00%

Tallett (Elizabeth E)

Independent Member of the Supervisory Board

47.22K

+4436.00%

Prof. Dr. Ross L. Levine, M.D.

Independent Member of the Supervisory Board

16.27K

+3835.00%

Prof. Dr. Elaine R. Mardis, Ph.D.

Independent Member of the Supervisory Board

3.97K

+3973.00%

Mr. Stephen H. (Steve) Rusckowski

Independent Chairman of the Supervisory Board

24.00

Dr. Toralf Haag, Ph.D.

Independent Member of the Supervisory Board

Dr. Eva Pisa, Ph.D.

Independent Member of the Supervisory Board

Mr. Bert van Meurs

Independent Member of the Supervisory Board

名稱

名稱/職務

職務

持股

持股變動

Mr. Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Board

383.09K

+143556.00%

Mr. Thierry Bernard

Chief Executive Officer, Managing Director, Member of the Executive Board

312.13K

+134537.00%

Dr. Metin Colpan, Ph.D.

Independent Member of the Supervisory Board

171.79K

-227680.00%

Tallett (Elizabeth E)

Independent Member of the Supervisory Board

47.22K

+4436.00%

Prof. Dr. Ross L. Levine, M.D.

Independent Member of the Supervisory Board

16.27K

+3835.00%

Prof. Dr. Elaine R. Mardis, Ph.D.

Independent Member of the Supervisory Board

3.97K

+3973.00%

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

業務USD

名稱

營收

佔比

Consumables and Related Revenues

481.20M

90.35%

Instrumentation

51.38M

9.65%

地區USD

名稱

營收

佔比

United States

286.67M

53.83%

Europe & Middle East & Africa

172.58M

32.40%

Asia, Pacific & Rest of the World

73.33M

13.77%

業務

地區

業務USD

名稱

營收

佔比

Consumables and Related Revenues

481.20M

90.35%

Instrumentation

51.38M

9.65%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Wellington Management Company, LLP

10.76%

MFS Investment Management

10.56%

The Vanguard Group, Inc.

4.30%

T. Rowe Price International Ltd

3.47%

DWS Investment GmbH

2.13%

其他

68.78%

持股股東

佔比

Wellington Management Company, LLP

10.76%

MFS Investment Management

10.56%

The Vanguard Group, Inc.

4.30%

T. Rowe Price International Ltd

3.47%

DWS Investment GmbH

2.13%

其他

68.78%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

48.66%

Investment Advisor

26.06%

Research Firm

5.08%

Pension Fund

1.63%

Sovereign Wealth Fund

1.60%

Hedge Fund

1.10%

Bank and Trust

1.09%

Individual Investor

0.44%

Insurance Company

0.07%

其他

14.27%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

988

176.43M

85.64%

-25.04M

2025Q3

996

177.81M

82.00%

-32.33M

2025Q2

996

189.55M

87.53%

+6.64M

2025Q1

1017

179.03M

82.67%

+27.58M

2024Q4

1010

129.03M

59.70%

-70.06M

2024Q3

1010

183.22M

84.72%

-23.62M

2024Q2

1002

184.34M

84.75%

+8.40M

2024Q1

988

165.20M

76.61%

-7.18M

2023Q4

993

165.11M

76.72%

-10.52M

2023Q3

987

159.93M

74.32%

-12.21M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Wellington Management Company, LLP

23.33M

10.76%

-2.69M

-10.35%

Sep 30, 2025

MFS Investment Management

22.91M

10.56%

-570.88K

-2.43%

Sep 30, 2025

The Vanguard Group, Inc.

9.33M

4.3%

+169.45K

+1.85%

Sep 30, 2025

T. Rowe Price International Ltd

7.52M

3.47%

+1.59M

+26.73%

Sep 30, 2025

DWS Investment GmbH

4.62M

2.13%

+1.32M

+39.94%

Sep 30, 2025

EARNEST Partners, LLC

4.21M

1.94%

+6.14K

+0.15%

Sep 30, 2025

Amundi Asset Management, SAS

4.15M

1.91%

+170.89K

+4.30%

Sep 30, 2025

Boston Partners

4.02M

1.85%

+594.42K

+17.37%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

3.98M

1.84%

-16.38M

-80.43%

Sep 30, 2025

BofA Global Research (US)

3.61M

1.66%

+2.63M

+269.19%

Oct 21, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

First Trust Nasdaq Lux Digi Health Solutions ETF

4.04%

Global X Genomics & Biotechnology ETF

3.81%

Invesco Biotechnology & Genome ETF

2.54%

VanEck Biotech ETF

1.79%

ROBO Global Healthcare Technology & Innovation ETF

1.51%

Pacer US Large Cap Cash Cows Growth Leaders ETF

1.26%

iShares Health Innovation Active ETF

1.21%

First Trust Health Care Alphadex Fund

0.91%

Franklin Genomic Advancements ETF

0.86%

WisdomTree International Multifactor Fund

0.72%

First Trust Nasdaq Lux Digi Health Solutions ETF

佔比4.04%

Global X Genomics & Biotechnology ETF

佔比3.81%

Invesco Biotechnology & Genome ETF

佔比2.54%

VanEck Biotech ETF

佔比1.79%

ROBO Global Healthcare Technology & Innovation ETF

佔比1.51%

Pacer US Large Cap Cash Cows Growth Leaders ETF

佔比1.26%

iShares Health Innovation Active ETF

佔比1.21%

First Trust Health Care Alphadex Fund

佔比0.91%

Franklin Genomic Advancements ETF

佔比0.86%

WisdomTree International Multifactor Fund

佔比0.72%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

May 07, 2025

QGEN.NB Final Cash Dividend of gross USD 0.25 paid on Jul 10, 2025 going ex on Jul 02, 2025

Jul 02, 2025

Jul 10, 2025

Jul 02, 2025

拆合股



公告日期

類型

比率

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

公告日期

類型

比率

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 17, 2025

Merger

36→35

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

Jan 18, 2024

Merger

25→24.25

常見問題

Qiagen NV的前五大股東是誰？



Qiagen NV的前五大股東如下：
Wellington Management Company, LLP
持有股份：23.33M
佔總股份比例：10.76%。
MFS Investment Management
持有股份：22.91M
佔總股份比例：10.56%。
The Vanguard Group, Inc.
持有股份：9.33M
佔總股份比例：4.30%。
T. Rowe Price International Ltd
持有股份：7.52M
佔總股份比例：3.47%。
DWS Investment GmbH
持有股份：4.62M
佔總股份比例：2.13%。